Emmarlinkpharma Profile
Key Indicators
- Authorised Capital ₹ 7.30 Cr
as on 17-11-2024
- Paid Up Capital ₹ 6.41 Cr
as on 17-11-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 20.27 Cr
as on 17-11-2024
- Satisfied Charges ₹ 15.00 Cr
as on 17-11-2024
- Revenue 16.45%
(FY 2023)
- Profit 0.37%
(FY 2023)
- Ebitda 11.58%
(FY 2023)
- Net Worth 10.21%
(FY 2023)
- Total Assets 37.29%
(FY 2023)
About Emmarlinkpharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.30 Cr and a paid-up capital of Rs 6.41 Cr.
The company currently has active open charges totaling ₹20.27 Cr. The company has closed loans amounting to ₹15.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramakrishnan Varayil, Girija Ramakrishnan, Aishwarya Praveen, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999KL2019PTC057236
- Company No.
057236
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Mar 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kannur, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Emmarlinkpharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramakrishnan Varayil  | Director | 24-Jan-2022 | Current |
| Girija Ramakrishnan | Director | 19-Mar-2019 | Current |
| Aishwarya Praveen | Director | 19-Mar-2019 | Current |
| Praveen Damodar | Director | 19-Mar-2019 | Current |
| Makkuni Ramakrishnan | Director | 19-Mar-2019 | Current |
Financial Performance of Emmarlinkpharma.
Emmarlinkpharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.45% increase. The company also saw a slight improvement in profitability, with a 0.37% increase in profit. The company's net worth Soared by an impressive increase of 10.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emmarlinkpharma?
In 2023, Emmarlinkpharma had a promoter holding of 88.37% and a public holding of 11.63%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Emmarlink Surgicals Private LimitedActive 2 years 8 monthsRamakrishnan Varayil and Girija Ramakrishnan are mutual person
- Emmar Drug Links Private LimitedActive 3 years 9 months
Ramakrishnan Varayil, Girija Ramakrishnan and 1 more are mutual person
- Kanhangad Links Private LimitedActive 3 years 7 months
Girija Ramakrishnan and Praveen Damodar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 10 May 2024 | ₹0.90 M | Open |
Dhanlaxmi Bank Limited Creation Date: 10 Jan 2024 | ₹0.68 M | Open |
Axis Bank Limited Creation Date: 12 May 2022 | ₹2.25 Cr | Open |
How Many Employees Work at Emmarlinkpharma?
Unlock and access historical data on people associated with Emmarlinkpharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emmarlinkpharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emmarlinkpharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
